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osting by EAbstract Background: Plasma amino acid concentrations have been reported to be abnormal in
patients with chronic renal failure. L-Arginine has been used to improve endothelial function by
increasing nitric oxide (NO) bioavailability.
The present study aim at investigating the status of plasma amino acids in pediatric patients with
chronic renal failure (CRF) on regular hemodialysis (HD) with and without history of thromboem-
bolic manifestations.
Methods: The study included 21 hemodialysis patients subdivided into two groups (those with no
history of thromboembolic manifestations and those with positive history of thromboembolic man-
ifestations) The control group included 13 age and sex matched apparently healthy subjects, After
careful history taking, clinical examination, the following laboratory investigations were performed:
serum calcium, phosphate, albumin, and creatinine (for controls only), complete blood count (CBC)
and serum amino acid analysis.
Results: HD patients had a significantly lower concentration of threonine, valine, methionine, leu-
cine, tyrosine, phenylalanine and tryptophane than the control group (p= 0.032, 0.020, 0.046,
0.011, 0.000, 0.022, and 0.004 respectively). There was no significant difference between HDom (M.E. Mowafy).
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74 M.A. El Sawy et al.patients and the control group as regard aspartic acid, serine, asparagine, glutamic acid, proline,
glycine, alanine, cystine, isoleucine, lysine, histidine, and arginine. The mean serum L-arginine level
was lower in 61.9% of HD patients than the mean of the controls with no significant difference.
L-Arginine concentration was not significantly different between HD patients with and without his-
tory of thromboembolic manifestations.
Conclusion: Several abnormalities in amino acids were present in HD patients compared to con-
trols. The mean serum L-arginine level was lower in 61.9% of HD patients than the mean of the
controls with no significant difference. L-Arginine concentration was not significantly different
between HD patients with and without history of thromboembolic manifestations. HD patients
without history of thromboembolic manifestations had significantly lower glutamic acid concentra-
tions and significantly higher phenylalanine concentrations than HD patients with history of throm-
boembolic manifestations.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The uremic syndrome is a complex condition that results from
an accumulation of multiple waste compounds, combined with
failure of the endocrine and homeostatic functions of the
kidney in end-stage chronic renal failure (CRF) patients [1].
Malnutrition is a common pathological condition which
exacerbates cardiovascular morbidity and mortality in chronic
renal failure patients.
The underlying mechanisms of malnutrition in CRF have
not been completely clarified. Inadequate diet and a state of
persistent catabolism play major roles [1]. Also protein metab-
olism changes with loss of renal function resulting in deteriora-
tion of nutritional status [2].
Levels of plasma and intracellular amino acids are signifi-
cant early indicators of protein metabolism and nutritional sta-
tus assessment [1,3]. Many of the characteristic alterations in
the plasma amino acid profile that are observed in chronic
end-stage renal disease are already present in mild renal insuf-
ficiency. Progressive loss of renal function generally results in
increasing abnormalities; these changes in plasma amino acid
concentrations were usually linear with reduction in glomeru-
lar filtration rate (GFR) [4].
Plasma protein and amino acid concentrations have been
reported to be abnormal in patients with CRF, whether on
conservative or regular dialysis treatment [5–8]. These abnor-
malities may be related to impaired protein and amino acid
metabolism, to dietary deficiencies of calories and proteins,
or to amino acid and protein losses due to peritoneal dialysis
or hemodialysis [9]. Moreover, branched-chain amino acids
are moderately decreased only in the advanced stage of renal
failure and this may be, at least in part, nutritional in origin
[6]. Also increased protein degradation may be the cause of in-
creased plasma concentration of nonessential amino acids in
malnourished chronic renal patients [2].
Increased cardiovascular mortality and morbidity is well
recognized in adults with CRF. The adverse impact of CRF
on cardiovascular mortality and morbidity in the young is
however even greater with a 500 times higher rate of cardiovas-
cular deaths than a control population. The initiation of vascu-
lar damage begins very early during the course of CRF, and
involves the vascular endothelium. L-Arginine is the substratefor nitric oxide (NO) synthase and has been shown to increase
endothelial function in animal models and in clinical studies of
subjects with hypercholesterolemia and coronary artery dis-
ease. So L-arginine supplementation in children with CRF
might increase NO bioavailability [1].2. Aim of the work
The aim of this work is to investigate the status of plasma ami-
no acids in pediatric patients with CRF on regular HD with
and without history of thromboembolic manifestations.3. Subjects and methods
This case control prospective study was conducted at the Pedi-
atric Nephrology Unit, Children’s Hospital, Ain Shams Uni-
versity, Cairo, Egypt, during the period from April 2008 to
February 2009.
It included 21 patients (12 males and nine females), their age
ranged from 9 to 18 years with a mean of 13.99 ± 2.794. Regar-
dinghe etiology of chronic renal failure in our studied patients, it
was glumerulonephrits in 11 patients (52%), Chronic paren-
chemtous Renal disease in six patients (29%), bilateral renal
stones in one patient (5%), Posterior uretheral valve and bilat-
eral 4th degree vesicoureteric reflex in one patient (5%), nephro-
calsinosis in one patient and the etiology was unknown in one
patient. Family history of chronic renal failure was negative in
our all our studied patients except for one patient who has Focal
Segmental glumerulonephrits. Parent consanguinity was pres-
ent among 10 (48%) of our studied patients.
Our patients were regularly dialyzed for 3–4 h/session,
thrice weekly sessions per week at a blood flow rate of
160–250 ml/min through arteriovenous fistula or grafts. All pa-
tients used bicarbonate dialysate (33 mmol/L; Fresenius Med-
ical Care, Germany) at a dialysate flow rate of 500 ml/min with
volumetric ultra filtration control. All HD treatments were
performed on either Gambro (AK-95, AK-200; Gambro
Corp., Sweden) or Fresenius (4008 B, or 4008 S; Fresenius
Medical Care, Germany) dialysis machines using low-flux
polysulfone synthetic hollow fiber (F3; F4 or F5; Fresenius
Medical Care, Germany). None of the patients reused the
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prepared from water obtained by reverse osmosis. Some of the
used dialysis machines were equipped with an endotoxin re-
moval filter, but the endotoxin concentration in dialysate fluids
was not measured in this study. Dialysis adequacy was esti-
mated using the kt/V method calculated by the machine (it
ranged between 0.9 and 1.4).
We excluded patients on hemodialysis with diabetes melli-
tus or nephrotic syndrome as an etiology of ESRD.
In addition, 13 age and sex matched apparently healthy
subjects were selected from relatives of patients as a control
group They were six males and seven females, their age ranged
from 5.5 to 18 years with a mean of 12.15 ± 3.72 years.
An informed oral consent was taken for the history taking,
physical examination and sample collection from the patients,
or their parents.
3.1. All children were subjected to
Full history taking with special emphasis on duration of dial-
ysis, thromboembolic manifestations (arteiovenous fistula
thrombosis, graft thrombosis, central vein thrombosis or
thrombosis in any other site), protein restriction diet and med-
ication history. Details of HD session and drugs were gathered
thorough history taking and review of patients’ files. They
were carefully examined with special emphasis on body weight,
height, edema, measurement of blood pressure ‘‘before dialysis
for the hemodialysis group’’ while subjects were quietly seated,
before withdrawing blood samples, cardiac and chest
examination.
Ten milliliters of venous blood were withdrawn without sta-
sis from the venous site of the arteriovenous fistula before the
start of the dialysis session (before heparin administration). In
the control group, blood samples were withdrawn from periph-
eral veins. The sample was divided to three parts one on
EDTA for CBC and two clotted samples. One for albumin,
Ca, P, the other one were centrifuged after clotting to obtain
the serum, aliquoted, and stored frozen at 20 C until used
for amino acid analysis.
 Serum calcium, phosphate, albumin, creatinine (for con-
trols only) assay were done immediately after sample collec-
tion using the auto analyzer 917 HITACHI, Boehringer
Mannheim, Germany.
 Complete blood count (CBC) using Coulter Corporation
model Gen’s Ana, program level 1.99195, S/WARE Kit
n/a, manufacture date, May 2001, Miami, FL 33196-2500.
 Amino acid analysis was done using The Amino Acid Ana-
lyzer SYKAM GmbH, Analytischer Messtechnik (Gewer-
bering 15, D_86922 Erosing, Germany in the Genetic
Research Center about 4 months later.
3.2. Method of amino acid analysis
Acid precipitation of proteins
 Plasma (800 lL) were pipetted in a centrifuge tube.
 Sulphosalicylic acid (200 lL) (10%) were added to the
plasma and the tube was shaken well.
 The mixture was stored in a refrigerator at 4 C for 30 min
and was then centrifuged for 10 min. The upper clear solution was dissolved with the sample
diluting buffer (Li citrate) in the ratio of one to one. (The
sample should show a pH-value of 1.80–2.00; if necessary,
the pH-value was corrected by using concentrated Lithium
hydroxide.
 The samples were analyzed shortly. Otherwise, it was frozen
till the assay time.
 Three standards were placed with patients samples in the
auto sampler. The similarity of the standards shows accu-
racy of amino acid analyzer.
3.3. Statistical methodology
Analysis of data was performed using standard computer pro-
gram Statistical Package for Social Sciences (SPSS)13.0 for
windows (SPSS Incorporation, USA). Normality of variable
distribution was tested by the Kolmogrov–Smirnov test. For
normally distributed data description of quantitative variables
in the form of mean ± standard deviation, and for non para-
metric data median, imterquartile ranges. Description of qual-
itative variables in the form of frequency and percentages.
Unpaired student t-test, and Mann–Whitney test were used
to analyze the differences between two groups for normal
and non-parametric variables respectively. Chi square test
was used to compare qualitative parameters.
Pearson’s and Spearman’s correlation coefficient tests were
used to correlate normal and non parametric variables, respec-
tively. Paired t-test was used to compare two readings of the
quantitative variable within the same group. Multiple regres-
sion analysis was used to find out the effect of different inde-
pendent factors on certain dependent variable using stepwise
technique. For all tests a probability (p) value of less than
0.05 was considered statistically significant, results were tabu-
lated and graphically represented using appropriate graphs
[10].
4. Results
HD patients had a significantly lower weight, OFC, calcium
and hemoglobin concentrations than the control group
(p= 0.029, 0.006, 0.009, and 0.001, respectively), and they
had a significantly higher phosphate concentration than the
control group (p 0.000). There was no significant difference be-
tween HD patients and the control group (p= 0.267, 0.082,
0.807, and 0.266) as regard age, height, alkaline phosphatase
and albumin (Table 1).
There was no significant difference between weight, height,
occipitofrontal circumference, mid arm circumference, systolic
blood pressure, diastolic blood pressure, age, age of onset of
dialysis, duration of dialysis, calcium, phosphate, albumin
and hemoglobin concentration in HD patients with and with-
out history of thromboembolic manifestations.
HD patients had a significantly lower concentration of thre-
onine, valine, methionine, leucine, tyrosine, phenylalanine and
tryptophane than the control group (p= 0.032, 0.020, 0.046,
0.011, 0.000, 0.022, and 0.004, respectively). There was no sig-
nificant difference between HD patients and the control group
as regard aspartic acid, serine, asparagine, glutamic acid, pro-
line, glycine, alanine, cystine, isoleucine, lysine, histidine, and
arginine. The mean serum L-arginine level was lower in
61.9% of HD patients than the mean of the controls with no
Table 1 Descriptive and comparative statistics of some demographic data and laboratory investigations done to HD patients and
controls.
HD (n = 21) Controls (n = 13) T/z* P Sig
Mean ± SD Median (IQR) Mean ± SD Median (IQR)
Age (years) 13.99 ± 2.794 14 (4) 12.15 ± 3.72 11 (6) 1.129 0.267 NS
Weight (kg) 28.071 ± 8.859 26.5 (8.3) 38.692 ± 16.549 35 (28.5) 2.163* 0.029 S
Height (cm) 130.14 ± 19.597 137 (27) 142.46 ± 18.59 141 (24) 1.761* 0.082 NS
OFC (cm) 53.29 ± 1.765 53 (2) 55 ± 1.871 55 (2) 2.737* 0.006 S
Ca (mg/dL) 8.495 ± 1.256 9 (2.1) 9.523 ± 0.5449 9.6 (1) 2.557* 0.009 S
P (mg/dL) 7.338 ± 1.795 7.4 (3.4) 3.938 ± 0.588 3.8 (1) 6.579 0.000 S
ALP (IU/L) 410.95 ± 401.07 212 (562) 258.77 ± 63.704 271 (112) 0.266* 0.807 NS
Alb (g/dL) 4.495 ± 0.376 4.5 (0.4) 4.654 ± 0.429 4.8 (0.9) 1.132 0.266 NS
Hb (g/dL) 8.91 ± 1.527 8.90 (2) 10.66 ± 1.243 10.7 (2) 3.478 0.001 S
HD: hemodialysis patients; SD: standard deviation; IQR: interquartile range; OFC: occipitofrontal circumference; Ca: calcium; P: phosphate;
ALP: alkaline phosphatase; Alb: Albumin; Hb: hemoglobin.
* Z value of Mann–Whitney test.
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concentration of threonine, valine, methionine, leucine, tyro-
sine, phenylalanine, and tryptophane than the control group
(p = 0.032, 0.020, 0.046, 0.011, 0.000, 0.022, and 0.004, respec-
tively). There was no significant difference between HD pa-
tients and the control group as regard aspartic acid, serine,
asparagine, glutamic acid, proline, glycine, alanine, cystine,
isoleucine, lysine, histidine, and arginine. The mean serum L-
arginine level was lower in 61.9% of HD patients than the
mean of the controls with no significant difference (Table 2).
HD patients without history of thromboembolic manifesta-
tions had significantly lower glutamic acid concentrations
(p = 0.03), and significantly higher phenylalanine concentra-
tions (p = 0.04) than HD patients with history of thromboem-
bolic manifestations (Table 3), on the other hand there was no
significant difference between HD patients with and without
history of thromboembolic manifestations as regard arginine
concentration (Table 3).
There was no significant difference between age, age of on-
set of symptoms, age of onset of dialysis, duration of dialysis,
weight, height, occipitofrontal circumference, mid arm circum-
ference, systolic, diastolic blood pressure, calcium, phosphate,Table 2 Comparison between HD patients and controls as regard
HD (n = 21)
Mean ± SD Median(IQR)
Aliphatic AA Glycine 115.24 ± 56.5638 107.7 (105.91)
Alanine 97.90 ± 61.2268 99.53 (86.19)
Valine 47.9 ± 17.391 52.44 (26)
Isoleucine 21.04 ± 12.1885 18.33 (18.64)
Leucine 42.58 ± 15.545 36.88 (17.83)
Hydroxyl AA Threonine 22.17 ± 14.10259 18.75 (23.46)
Serine 353.29 ± 922.236 44.97 (38.14)
Sulfur AA Cystine 12.01 ± 6.0586 13.035 (11)
Methionine 11.54 ± 6.775 9.97 (7.03)
Acidic AA, amides Aspartic acid 23.87 ± 48.578 1.24 (10.7)
Asparagine 754.88 ± 1030.939 118.16 (1854.1
Glutamic acid 10.14 ± 13.806 3.22 (11.4)
Basic AA Arginine 35.03 ± 24.884 33.32 (47.28)
Lysine 56.59 ± 21.4578 50.36 (29.45)
Histidine 17.77 ± 11.08 15.67 (20.35)
Aromatic AA Tyrosine 16.85 ± 10.479 14.115 (15.72)
Phenylalanine 30.29 ± 13.0493 27.82 (21.43)
Tryptophane 13.46 ± 9.643 11.53 (19.35)
Imino acids Proline 128.35 ± 104.793 115.93 (203.7)
HD: hemodialysis patients; SD: standard deviation; IQR: interquartile ra
* Z value of Mann–Whitney test (for non parametric data).albumin, hemoglobin concentrations, between HD patients
with low or normal arginine concentration.
HD patients with low arginine concentration had signifi-
cantly lower concentrations of tyrosine and phenylalanine ami-
no acids than those with normal arginine concentration
(Patients who had L-arginine levels compared to the lowest
normal level for L-arginine (normal L-arginine level 44–
120 lmol/L [11] were 13 patients. Those 13 patients identified
as patients with low arginine) (Table 4).
5. Discussion
Cardiovascular disease is a major cause of mortality among
patients with chronic renal failure (CRF) [12]. The vascular
damage in dialyzed patients is frequently observed and it is
probable that disturbances in fibrinolytic activity and endothe-
lial dysfunction may play a role in vascular complications such
as stroke or ischemic heart disease [13].
Chronic renal failure patients display endothelial dysfunc-
tion, a critical element in the pathogenesis of atherosclerosis.
Upon activation or apoptosis, the endothelium sheds micro-
particles are considered as markers of endothelial dysfunction,serum amino acids.
Control (n = 13) T/z* P Sig
Mean ± SD Median(IQR)
113.61 ± 74.707 91.72 (65.95) 0.066 0.948 NS
605.16 ± 926.45 224.4 (622.0) 1.811* 0.074 NS
87.15 ± 45.983 75.56 (81) 2.324* 0.020 S
26.09 ± 10.788 29.49 (15.57) 1.153 0.259 NS
64.38 ± 26.1536 64.08 (35.92) 2.725 0.011 S
41.36 ± 27.286 34.39 (38.36) 2.280 0.032 S
207.62 ± 423.85 69.1 (94.55) 1.300 0.205* NS
24.38 ± 23.19 17.79 (9.5) 1.483 0.146* NS
16.65 ± 7.66 17.38 (13.94) 2.002 0.046* S
13.01 ± 34.403 1.725 (7.69) 0.062 0.976* NS
9) 218.98 ± 199.817 145.5 (401.5) 0.169 0.902* NS
62.25 ± 44.11 56.13 (84.12) 3.001 0.002* NS
46.66 ± 88.8127 17.5 (39.03) 1.143 0.267* NS
139.35 ± 263.35 67.38 (35.09) 1.012 0.330* NS
35.32 ± 25.385 37.97 (51.68) 1.804 0.091 NS
40.27 ± 21.379 33.72 (33.81) 4.042 0.000 S
43.48 ± 16.738 44.51 (19.55) 2.428 0.022 S
.49 ± 5.3606 1.54 (5.29) 2.831 0.004* S
73.81 ± 38.565 64.17 (40.3) 1.281 0.229 NS
nge. Amino acids concentrations measured by lMol/L.
Table 3 Comparison between HD patients with and without history of thromboembolic manifestations.
No history of thromboembolic
manifestations (n = 12)
Positive history of thromboembolic
manifestations (n = 9)
T/z* P Sig
Mean ± SD Median (IQR) Mean ± SD Median (IQR)
Aliphatic AA Glycine 125.75 ± 67.38 115.19 (121.14) 103.41 ± 42.69 95.33 (64.95) 0.804 0.434 NS
Alanine 98.5 ± 63.43 103.76 (117.4) 97.13 ± 63.29 95.3 (82.98) 0.265* 0.837 NS
Valine 53.64 ± 19.44 55.43 (23) 42.17 ± 13.96 42.97 (29) 1.26* 0.234 NS
Isoleucine 26.54 ± 14.89 24.27 (22.86) 16.23 ± 7.09 16.46 (8.91) 1.751 0.103 NS
Leucine 47.97 ± 13.36 50.26 (22.21) 37.86 ± 16.60 34.67 (10.39) 1.285 0.221 NS
Hydroxyl AA Threonine 26.94 ± 16.77 25.35 (32.95) 15.82 ± 6.20 17.24 (10.94) 1.535 0.151 NS
Serine 384.96 ± 1072.8 49.51 (18.24) 300.49 ± 688.89 23.43 (443.63) 1.73* 0.093 NS
Acidic AA, amides Aspartic acid 43.23 ± 61.08 9.995 (105.24) 0.65 ± 0.53 0.06 (0.96) 1.826* 0.082 NS
Asparagine 773.27 ± 1069.98 142.68 (1789.8) 699.72 ± 1122.5 93.65 0.277* 0.864 NS
Glutamic acid 17.25 ± 15.68 10.49 (29.63) 1.6 ± 1.44 2.16 (2.76) 2.191* 0.03 S
Sulfur AA Cystine 10.99 ± 5.73 12.77 (10.66) 13.60 ± 6.66 17.13 (13.05) 1.132* 0.285 NS
Methionine 12.27 ± 7.52 10.165 (9.01) 10.57 ± 5.92 9.97 (3.3) 0.284* 0.808 NS
Aromatic AA Tryptophane 16.32 ± 9.02 16.64 (12.78) 8.44 ± 9.73 4.42 (16.08) 1.323* 0.230 NS
Tyrosine 21.29 ± 11.69 19.16 (20.17) 12.41 ± 7.23 13.36 (7.33) 1.937 0.071 NS
Phenylalanine 37.03 ± 14.09 40.715 (25.26) 24.31 ± 9.01 23.86 (11.16) 2.247 0.040 S
Basic AA Lysine 57.74 ± 19.52 50.36 (25.48) 55.58 ± 24.32 52.83 (33.71) 0.347* 0.779 NS
Histidine 16.61 ± 13.52 14.06 (25.54) 18.92 ± 10.01 16.86 (18.69) 0.275 0.792 NS
Arginine 39.27 ± 26.56 47.815 (50.99) 29.73 ± 23.22 24.37 (42.19) 0.622* 0.573 NS
Imino acids Proline 141.77 ± 99.96 115.93 108.21 ± 50.30 108.21 0.309 0.778 NS
HD: hemodialysis patients; SD: standard deviation; IQR: interquartile range. Amino acids concentrations measured by lMol/L.
* Z value of Mann–Whitney test (for non parametric data).
Table 4 Comparison between HD patients with low and with normal arginine.
Low arginine (n = 13) Normal arginine (n = 8) T/z* P Sig
Mean ± SD Median(IQR) Mean ± SD Median(IQR)
Aliphatic AA Glycine 110.04 ± 65.25 81.47 (115.45) 122.67 ± 45.12 115.19 (75.31) 0.442 0.665 NS
Alanine 73.298 ± 57.56 74.56 (102.12) 138.91 ± 45.31 136.64 (87.17) 1.952* 0.056 NS
Valine 45.96 ± 20.63 45.64 (31) 51.14 ± 10.99 55.45 (17) 1.085* 0.313 NS
Isoleucine 18.31 ± 13.70 14.6 (11.69) 25.14 ± 9.05 24.89 (15.92) 1.068 0.305 NS
Leucine 36.88 ± 13.64 33.93 (18.96) 51.13 ± 15.25 49.51 (26.91) 1.894 0.081 NS
Hydroxyl AA Threonine 15.31 ± 5.98 16.65 (10.4) 29.04 ± 16.88 31.94 (33.21) 2.028 0.065 NS
Serine 536.39 ± 1148.04 37.59 (455.6) 48.12 ± 18.61 50.35 (24.85) 1.085* 0.313 NS
Acidic AA,amides Aspartic acid 21.24 ± 54.46 0.85 (1034) 28.48 ± 43.46 9.99 (70.04) 1.323* 0.23 NS
Asparagine 569.42 ± 911.11 118.16 (1529.13) 1125.81 ± 1298.05 840.04 (2386.82) 0.679* 0.57 NS
Glutamic acid 7.27 ± 13.13 2.31 (9.58) 13.57 ± 15.28 7.81 (22.78) 1.278* 0.247 NS
Sulfur AA Cystine 12.71 ± 5.18 13.3 (8.49) 10.89 ± 7.54 11.24 (16.94) 0.498* 0.659 NS
Methionine 11.06 ± 7.40 8.83 (6.4) 12.32 ± 6.01 11.84 (6.39) 1.05* 0.301 NS
Aromatic AA Tryptophane 10.431 ± 7.52 11.08 (13.09) 18.75 ± 11.74 20.93 (22.08) 1.32* 0.230 NS
Tyrosine 12.81 ± 10.40 11.46 (8.43) 23.20 ± 7.33 21.39 (14.28) 2.29 0.036 S
Phenylalanine 25.74 ± 12.34 23.86 (14.69) 38.64 ± 10.51 40.82 (15.03) 2.16 0.047 S
Basic AA Lysine 61.28 ± 21.37 62.2 (25.78) 49.55 ± 21.42 45.35 (27.18) 1.17* 0.272 NS
Histidine 13.25 ± 10.74 10.23 (15.5) 25.29 ± 7.92 21.96 1.66 0.146 NS
Arginine 15.26 ± 10.22 12.89 (11.68) 59.74 ± 10.64 60.18 (22.81) 3.55* 0.000 S
Imino acids Proline 29.60 ± 39.13 29.61 194.18 ± 70.32 214.49 2.92 0.061 NS
HD: hemodialysis patients; SD: standard deviation; IQR: interquartile range. Amino acids concentrations measured by lMol/L.
* Z value of Mann–Whitney test (for non parametric data).
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dysfunction is regarded as the initial reversible step in the
development of atherosclerosis and has been demonstrated in
all stages of renal failure, it may reflect increased atherogenic
and thrombogenic properties of the endothelium, contributing
to subsequent adverse cardiovascular outcome [11].
Reduced activity of the nitric oxide (NO) pathway has been
implicated in the endothelial dysfunction that occurs in pa-
tients with renal failure. NO is generated from L-arginine by
NO synthase, and certain uremic toxins including asymmetri-
cal dimethyl-L-arginine (ADMA), inhibit NO synthase and
might contribute to endothelial dysfunction [15].The present study showed that serum leucine and valine
were significantly lower in HD patients than in the control
group. This is in accordance with [16] who reported that plas-
ma leucine and valine levels were significantly decreased in ure-
mic children from those in the controls. [17] reported that the
low plasma and cellular valine together with low plasma leu-
cine are secondary to abnormal muscle and hepatosplanchnic
AA metabolism. In muscle, metabolic acidosis induces protein
breakdown via an activation of both cytosolic ATP-ubiquitin–
dependent proteolytic pathway and BCKA dehydrogenase,
responsible for an irreversible BCAA breakdown. The de-
crease in hepatosplanchnic retention of nonessential AAs con-
78 M.A. El Sawy et al.tributes to the abnormalities of arterial AAs associated with
renal insufficiency. Moreover, a significant decrease of
branched chain AA concentration is related to calorie-protein
malnutrition, inflammation, and a long period of hemodialysis
[10].
In the current study there was a significantly lower serum
tryptophane in HD patients compared to the control group.
Laurence et al. (2007) [18] confirmed the reduction in plasma
tryptophan in patients on dialysis. They reported that plasma
tryptophan concentration is reduced in CRF patients that is in
turn associated with elevated precursors of tryptophan metab-
olism, including l-kynurenine and quinolinic acid, both of
which have been implicated in the neurotoxic manifestations
of CRF. Druml et al. (1994) [19] suggested that binding of
tryptophan to albumin is reduced because of the accumulation
of competing solutes in the plasma leading to acceleration of
tryptophan metabolism by the fall in the protein bound frac-
tion associated with elevated tryptophan clearance. Our result
is in contrary with Schefold et al. (2009) [9] who investigated
tryptophane catabolism, indoleamine 2,3-dioxygenase activity
(the enzyme that catabolizes tryptophane) and the role of
inflammation in moderate to very severe CKD and hemodial-
ysis in 40 adult CKD patients aged 57 ± 14 years with differ-
ent stages of renal disease. They reported that tryptophane
levels were unchanged in CKD, indoleamine 2,3-dioxygenase
activity and serum levels of tryptophan catabolites of the kyn-
urenine pathway increase with CKD severity. In CKD, induc-
tion of indoleamine 2,3-dioxygenase may primarily be a
consequence of chronic inflammation. The difference between
our study and their study may be related to the difference in
age distribution (adult vs. pediatric), and severity of renal dis-
ease (patients at different stages of renal disease vs. hemodial-
ysis patients).
The present study showed a significantly lower serum tyro-
sine and phenylalanine in HD patients compared to the control
group. This is in accordance with Canepa et al. (1992) [16] who
reported that plasma tyrosine was significantly decreased in
uremic children compared to controls, which may be explained
according to Kopple (2007) [20] by the impairment in the con-
version of phenylalanine to tyrosine in CRF patients as the
conversion of phenylalanine to tyrosine to a large extent takes
place in the kidneys. Similarly, Yokoyama et al. (2002) [21]
found that the reduction of quinoid type BH2 to BH4 is mod-
ified in patients with CRF which may play a role in the im-
paired phenylalanine hydroxylase activity.
In the current study there was significantly lower serum
methionine in HD patients compared to the control group.
This may be due to the high clearance of methionine in HD pa-
tients [18]. This contradicts with Suliman et al. (2002) [8] who
examined the relationship of plasma sulfur amino acids to car-
diovascular disease and nutritional status in 151 patients with
CRF close to the start of regular dialysis treatment. They re-
ported that plasma methionine level was normal. The differ-
ence between this study and that of Suliman et al. (2002) [8]
may be related to the difference in dialysis duration (patients
on dialysis for >6 months vs. patients close to the start of reg-
ular dialysis treatment) and the different number of patients.
In the current study serum threonine was significantly re-
duced in HD patients compared to the controls. This is in
accordance with Bergström et al. (1990) [22] who stated that
in the hemodialysis patients threonine was significantly
reduced in plasma compared to the controls.The present study showed that 61.9% of HD patients had
lower L-arginine levels compared to the normal level for L-argi-
nine (normal L-arginine level [23]. However, lower L-arginine
in HD patients was not significant. This is in accordance with
Kielstein et al. (1999) [24] who found that plasma L-arginine
concentrations were not significantly decreased in patients with
ESRD. Moreover, Schmidt et al. (1999) [25] stated that plasma
arginine level was normal and plasma levels of citrulline and
the endogenous NOS Inhibitor, ADMA, were markedly ele-
vated in patients with ESRD compared to controls. The
hemodialysis patients had, as a whole, less abnormal free ami-
no acid concentrations in plasma and muscles, compared to
patients with untreated chronic uremia, although the general
pattern tended to be similar. Muscle arginine was low in the
untreated patients. However, it was not significantly decreased
in the hemodialysis patients. This may presumably be a conse-
quence of higher protein intake and better nutritional status in
the hemodialysis patients than in the non-dialyzed patients in
whom anorexia might have adversely affected the intake of
nutrients [21].
Abnormalities in amino acids in chronic uremia have been
attributed to low protein intake, deficiency of excretory and
metabolic functions of the diseased kidneys, toxic effects of
uremia on the intermediary metabolism of amino acids, altered
distribution of some amino acids between the extra- and intra-
cellular compartments and, in dialysis patients, loss of protein
and amino acids by the dialytic procedure [21] .
Malnutrition may be one of the causes of AA abnormalities
detected in these HD patients, as evidenced by the significant
lower weight and OFC in HD patients compared to the control
group. Also, serum albumin was lower in HD patients com-
pared to the control group. However, this was not statistically
significant. The insignificant difference in serum albumin may
be explained by the fact that no one of our patients was on
protein restriction diet. This is in accordance with Sen and
Prakash (2000) [26], who found that malnutrition is a common
clinical problem in dialysis patients, which is multifactorial in
origin, and Magorzewicz et al. (2008) [27] who reported that
despite quite good nutritional status, dialyzed patients have
abnormalities in their AA profiles. This is in contrary with Se-
zer et al. (2007) [28], who reported that in their patients there
were 34 hypoalbuminemic and 34 normoalbuminemic patients.
The difference between this study and their study may be re-
lated to the difference in patients groups (CRF patients on
hemodialysis vs. hemodialysis, continuous ambulatory perito-
neal dialysis and predialytic patients).
There was no significant difference between HD patients
with and without history of thromboembolic manifestations
(arteiovenous fistula thrombosis, graft thrombosis, central vein
thrombosis or thrombosis in any other site) as regard age, cal-
cium, phosphate, alkaline phosphatase, albumin and hemoglo-
bin concentration.
The present study showed that serum glutamic acid concen-
tration was significantly lower in HD patients without history
of thromboembolic manifestations compared to those with his-
tory of thromboembolic manifestations. Morrell et al. (2008)
[13]reported that despite the presence of glutamate in platelet
granules, the role of glutamate during hemostasis is under re-
search, they showed that activated platelets release glutamate,
that platelets express alpha-amino-3-hydroxy-5-methyl-4-isox-
azolepropionic acid (AMPA) receptor (AMPAR) subunits,
and that glutamate increases agonist-induced platelet activa-
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the AMPAR increases intracellular sodium concentration and
depolarizes platelets, which are important steps in platelet acti-
vation. In contrast, platelets treated with the AMPAR antag-
onist CNQX or platelets derived from GluR1 knockout mice
are resistant to AMPA effects. Importantly, mice lacking
GluR1 have a prolonged time to thrombosis in vivo their data
identify glutamate as a regulator of platelet activation,
and suggested that the AMPA receptor is a novel antithrom-
botic target. Thus we suggest a state of chronic platelet activa-
tion in HD patients with history of thromboembolic
manifestations.
The present study showed that serum phenylalanine was
significantly lower in HD patients with history of thromboem-
bolic manifestations than those without history of thromboem-
bolic manifestations. Zhang et al. (2009) [29] used an ultra fast
liquid chromatography coupled with IT-TOF mass spectrom-
etry (UFLC/MS-IT-TOF) metabonomic approach to study
the plasma and urine metabolic profiling of atherosclerosis
rats, potential biomarkers were screened by using S-plot and
were identified by the accurate mass and MS(n) fragments.
They reported that concentrations of leucine, phenylalanine,
tryptophan, acetylcarnitine, butyrylcarnitine, propionylcarni-
tine and spermine in plasma decreased in atherosclerosis rats.
The alternated metabolites demonstrated abnormal metabo-
lism of phenylalanine, tryptophan, bile acids and amino acids.
There research proved that metabonomics is a promising tool
for disease research.
In conclusion, several abnormalities in amino acids were
present in HD patients compared to controls in the form of
significantly lower serum concentration of threonine, valine,
methionine, leucine, tyrosine, phenylalanine and tryptophane
than the control group. There were low concentrations of
aspartic acid, serine, asparagine, glutamic acid, alanine, cys-
tine, isoleucine, lysine, histidine and arginine with no signifi-
cant difference. There were high concentrations of glycine
and proline with no significant difference. The mean serum
L-arginine levels were lower in 61.9% of HD patients than
the mean of the controls with no significant difference. L-
Arginine concentration was not significantly different be-
tween HD patients with and without history of thromboem-
bolic manifestations. HD patients without history of
thromboembolic manifestations had significantly lower glu-
tamic acid concentrations and significantly higher phenylala-
nine concentrations than HD patients with history of
thromboembolic manifestations.
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